Cargando…
From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735665/ https://www.ncbi.nlm.nih.gov/pubmed/31555485 http://dx.doi.org/10.1136/esmoopen-2019-000548 |
| _version_ | 1783450390589603840 |
|---|---|
| author | Pirker, Robert Filipits, Martin |
| author_facet | Pirker, Robert Filipits, Martin |
| author_sort | Pirker, Robert |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6735665 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | BMJ Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-67356652019-09-25 From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer Pirker, Robert Filipits, Martin ESMO Open Editorial BMJ Publishing Group 2019-09-08 /pmc/articles/PMC6735665/ /pubmed/31555485 http://dx.doi.org/10.1136/esmoopen-2019-000548 Text en © Author (s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
| spellingShingle | Editorial Pirker, Robert Filipits, Martin From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer |
| title | From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer |
| title_full | From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer |
| title_fullStr | From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer |
| title_full_unstemmed | From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer |
| title_short | From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer |
| title_sort | from crizotinib to lorlatinib: continuous improvement in precision treatment of alk-positive non-small cell lung cancer |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735665/ https://www.ncbi.nlm.nih.gov/pubmed/31555485 http://dx.doi.org/10.1136/esmoopen-2019-000548 |
| work_keys_str_mv | AT pirkerrobert fromcrizotinibtolorlatinibcontinuousimprovementinprecisiontreatmentofalkpositivenonsmallcelllungcancer AT filipitsmartin fromcrizotinibtolorlatinibcontinuousimprovementinprecisiontreatmentofalkpositivenonsmallcelllungcancer |